Unknown

Dataset Information

0

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.


ABSTRACT:

Background

Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib + gemcitabine ± cisplatin in patients with resistant/refractory advanced solid tumours.

Methods

We evaluated the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of intravenous berzosertib + gemcitabine ± cisplatin using a standard 3 + 3 dose-escalation design. The starting doses were berzosertib 18 mg/m2, gemcitabine 875 mg/m2 and cisplatin 60 mg/m2.

Results

Fifty-two patients received berzosertib + gemcitabine and eight received berzosertib + gemcitabine + cisplatin. Four patients receiving berzosertib + gemcitabine had a total of seven dose-limiting toxicities (DLTs) and three receiving berzosertib + gemcitabine + cisplatin had a total of three DLTs. Berzosertib 210 mg/m2 (days 2 and 9) + gemcitabine 1000 mg/m2 (days 1 and 8) Q3W was established as the recommended Phase 2 dose (RP2D); no RP2D was determined for berzosertib + gemcitabine + cisplatin. Neither gemcitabine nor cisplatin affected berzosertib PK. Most patients in both arms achieved a best response of either partial response or stable disease.

Conclusions

Berzosertib + gemcitabine was well tolerated in patients with advanced solid tumours and showed preliminary efficacy signs.

Clinical trial identifier

NCT02157792.

SUBMITTER: Middleton MR 

PROVIDER: S-EPMC8368196 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5876726 | biostudies-literature
| S-EPMC8367944 | biostudies-literature
| S-EPMC4170644 | biostudies-literature
| S-EPMC5632222 | biostudies-literature
| S-EPMC7499606 | biostudies-literature
| S-EPMC4252598 | biostudies-literature
| S-EPMC7611191 | biostudies-literature
| S-EPMC3495895 | biostudies-literature
| S-EPMC7870753 | biostudies-literature
| S-EPMC8458434 | biostudies-literature